|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:acquired
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:acquisition
|
gptkb:2008
to enhance product portfolio
|
|
gptkbp:business_model
|
gptkb:Company
biopharmaceuticals
biotech development and commercialization
|
|
gptkbp:ceo
|
gptkb:David_S._Waksal
gptkb:John_Johnson
|
|
gptkbp:clinical_trial
|
multiple
ongoing
positive
Phase III
targeted therapy
Phase III trials
published in journals
multiple ongoing
Erbitux in 2004
extensive clinical trial data
|
|
gptkbp:collaborations
|
academic institutions
numerous
with leading cancer research centers
|
|
gptkbp:committee
|
established
|
|
gptkbp:community_engagement
|
active
support for local health initiatives
|
|
gptkbp:competitors
|
gptkb:Genentech
gptkb:Roche
gptkb:Amgen
|
|
gptkbp:employees
|
over 500
approximately 300
approximately 500
|
|
gptkbp:financial_performance
|
strong revenue growth
strong in 2008
|
|
gptkbp:focus
|
gptkb:healthcare_organization
head and neck cancer
|
|
gptkbp:focus_area
|
gptkb:healthcare_organization
|
|
gptkbp:founded
|
gptkb:Im_Clone_Systems,_Inc.
gptkb:New_York_City,_New_York
gptkb:1984
gptkb:Samuel_D._Waksal
|
|
gptkbp:founder
|
gptkb:Samuel_D._Waksal
Samuel Waksal
|
|
gptkbp:future_plans
|
expansion of product line
|
|
gptkbp:global_presence
|
operations in multiple countries
|
|
gptkbp:governed_by
|
strong
|
|
gptkbp:has_specialty
|
in monoclonal antibody development
|
|
gptkbp:headcount
|
300 employees
|
|
gptkbp:headquarters
|
gptkb:Borough
gptkb:New_York_City,_New_York
|
|
gptkbp:healthcare
|
Erbitux in 2004
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Im Clone Systems
|
|
gptkbp:industry
|
gptkb:Company
gptkb:drug
|
|
gptkbp:invention
|
multiple patents on cancer therapies
numerous in oncology
|
|
gptkbp:investment
|
active
various institutional investors
in R& D
significant in R& D
high in 2008
strong in 2008
|
|
gptkbp:key_people
|
gptkb:David_S._Waksal
gptkb:L._Patrick_Gage
gptkb:William_H._Goodwin
gptkb:John_A._Mc_Kinley
gptkb:John_Johnson
gptkb:David_A._Kessler
gptkb:Richard_A._Heyman
gptkb:M._Christine_Jacobs
gptkb:Robert_A._Ingram
gptkb:Robert_J._Hugin
gptkb:Michael_A._Mc_Coy
gptkb:John_C._Lechleiter
gptkb:Samuel_D._Waksal
Richard L. Schilsky
|
|
gptkbp:language
|
innovation-driven
|
|
gptkbp:language_of_instruction
|
multiple candidates
|
|
gptkbp:location
|
gptkb:New_York
gptkb:United_States
|
|
gptkbp:market
|
global
Erbitux in 2004
leader in oncology therapeutics
|
|
gptkbp:market_cap
|
$6.5 billion (2021)
$2 billion (2008)
|
|
gptkbp:marketing_strategy
|
focused on oncology
growth through innovation
focus on targeted therapies
|
|
gptkbp:net_worth
|
$50 million (2008)
|
|
gptkbp:notable_achievement
|
FDA approval for Erbitux
|
|
gptkbp:notable_allies
|
various partners
|
|
gptkbp:notable_products
|
gptkb:Erbitux
|
|
gptkbp:partnership
|
gptkb:Bristol-Myers_Squibb
various global pharmaceutical companies
|
|
gptkbp:partnerships
|
various pharmaceutical companies
|
|
gptkbp:philanthropy
|
support for cancer research
|
|
gptkbp:products
|
gptkb:Erbitux
gptkb:monoclonal_antibody
ongoing
biopharmaceuticals
multiple candidates in development
|
|
gptkbp:publishes
|
numerous
numerous peer-reviewed articles
|
|
gptkbp:receives_funding_from
|
secured
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
various international approvals
|
|
gptkbp:research
|
gptkb:Dr._David_M._Hyman
|
|
gptkbp:research_and_development
|
oncology
|
|
gptkbp:research_areas
|
various
oncology
monoclonal antibodies
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
monoclonal antibodies
biologics
cancer therapeutics
EGFR inhibitors
|
|
gptkbp:research_interest
|
gptkb:significant
|
|
gptkbp:revenue
|
$1.2 billion (2020)
$200 million (2008)
|
|
gptkbp:scientific_name
|
composed of leading experts
|
|
gptkbp:social_responsibility
|
initiatives
|
|
gptkbp:subsidiary
|
gptkb:Eli_Lilly_and_Company
Im Clone LLC
|
|
gptkbp:sustainability_initiatives
|
environmental responsibility programs
|
|
gptkbp:symbol
|
IMCL
|
|
gptkbp:team
|
experienced
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.imclone.com
|